| Nov 13 |
Pieris Pharmaceuticals: Q3 Earnings Snapshot
|
| Nov 7 |
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
|
| Aug 19 |
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)
|
| Aug 17 |
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
|
| Jul 24 |
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
|
| Jul 24 |
Pieris Pharma surges on all-stock merger deal
|
| Jul 24 |
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
|
